Proviron 25mg/tab 100 Tabletten by Dragon-Pharma

Usage

1. Schedule your mild-cycle PCT start date before the cycle ends — calculate when the cycle's last compound falls below active concentration, then begin mesterolone the following day rather than waiting for symptoms to appear.
2. Take one 25 mg tablet daily with food; consuming mesterolone alongside a meal containing dietary fat improves oral absorption due to the compound's lipophilic character.
3. Maintain consistent daily timing — morning dosing is preferred by most mild-cycle users because it aligns peripheral androgenic support with the natural cortisol peak and daily activity window.
4. If co-administering a SERM, take mesterolone and the SERM at different times of day to reduce any competitive interaction at intestinal absorption level; a morning/evening split is a practical approach.
5. Monitor subjective markers — libido, morning erections, training energy — weekly throughout the 4-week protocol; these are the most accessible indicators that free androgen availability is being adequately maintained during recovery.
6. Obtain post-PCT bloodwork at the end of week 4 and again at week 6 off-cycle; total testosterone, free testosterone, LH, FSH, and SHBG values confirm whether the mild-cycle recovery has completed successfully before planning any subsequent cycle.

Warnings

Frequently asked questions

Do you actually need PCT after a mild cycle, or can you skip it entirely?

A mild cycle does suppress the HPG axis, even if minimally — skipping recovery altogether risks a prolonged window of low-free-androgen symptoms including reduced libido, flat mood and slow strength retention. A short mesterolone-based mini-PCT bridges that window efficiently. Most mild-cycle users recover naturally within 6–8 weeks; a structured 4-week protocol with 25 mg mesterolone daily shortens the symptomatic phase noticeably.

How short can a mini-PCT realistically be after a mild anabolic cycle?

For truly mild cycles — single compound, short duration, low dose — a 3 to 4-week PCT is generally sufficient. Mesterolone is well-suited to this compressed timeline because it acts peripherally and does not require a taper-down phase itself. Many users run 4 weeks flat at 25 mg daily and report full symptomatic recovery, confirmed by bloodwork showing testosterone in the normal reference range by week four post-cycle.

Which SERM pairs well with mesterolone for a low-suppression recovery?

For mild suppression, a low-dose SERM such as clomiphene at 25 mg daily or tamoxifen at 10–20 mg daily is typically sufficient to stimulate gonadotropin output. Mesterolone runs alongside it to maintain peripheral androgenic tone during the SERM stimulation phase. This pairing keeps the total protocol conservative — both agents at their lowest effective doses — appropriate for the degree of suppression a mild cycle creates.

Why is the 25 mg tablet concentration considered the reference dose for mesterolone?

The 25 mg per tablet format mirrors the original clinical dosing unit established in andrology practice, where mesterolone was used to treat androgen insufficiency and male hypogonadism. Dragon-Pharma Proviron reproduces this unit exactly, meaning each tablet equals one standard clinical dose. At 25 mg/tab, users can dose one tablet daily for a conservative mild-cycle bridge or two tablets for moderate support — no splitting required, and no accumulated measurement error.

How many PCT cycles does one 100-tablet jar of Dragon-Pharma Proviron cover?

At the standard mild-cycle protocol of 25 mg per day for 28 days, one jar provides exactly 100 doses — sufficient for four complete 25-day mini-PCT courses or three and a half 28-day courses. For users running mild cycles two to three times per year, a single 100-tablet jar provides a full training year's worth of PCT androgenic support at the conservative dose tier, representing strong value per recovery cycle. (2) angle_used

Manufacturer

Dragon-Pharma's oral androgen portfolio spans a broad concentration range — from low-unit-dose compounds used in clinical-style protocols to high-dose performance compounds — and Proviron 25 mg sits at the foundational reference-dose tier of that range. What unifies the entire oral line is the same release architecture: no finished tablet batch enters distribution until it has cleared a sequential two-gate quality process in which raw mesterolone API is identity-confirmed before blending and finished compressed tablets are sampled and quantified by HPLC against a certified reference standard after compression. This process is not marketing language — it converts the printed label dose into a batch-specific, analytically documented figure. The 100-tablet jar format used for Proviron reflects Dragon-Pharma's broader formulation philosophy for multi-use oral products: sufficient pack volume to serve repeat-use PCT applications while maintaining primary seal integrity until the user opens the jar. Dragon-Pharma's GMP-compliant production environment, covering API dispensing through to primary packaging, ensures that the batch records accompanying each lot of Proviron tablets provide an unbroken traceability chain from incoming raw material to the tablet in the user's hand.